Evidence map›Paper›PMID 42236116›Full record

ArticleJournal for immunotherapy of cancer2026

Repurposing COVID-19 (and other) mRNA vaccines to boost cancer immunotherapy efficacy: mechanistic insights and future directions.

Shashi Gujar, Jonathan G Pol, Vishnu Vijay Vijayan, Preethi Gopalakrishnan Nair, Unnikrishnan Babukuttan Sheela, Anurag Banerjee, Guido Kroemer

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal for immunotherapy of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Shashi Gujar *Pathology, Faculty of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada shashi.gujar@dal.ca.
Jonathan G Pol *U1138, Cordeliers Research Center, INSERM, Paris, France.ORCID http://orcid.org/0000-0002-8355-7562
Vishnu Vijay VijayanDepartment of Pathology, Dalhousie University, Halifax, Nova Scotia, Canada.
Preethi Gopalakrishnan NairBeatrice Hunter Cancer Research Institute, Halifax, Nova Scotia, Canada.
Unnikrishnan Babukuttan SheelaDepartment of Pathology, Dalhousie University, Halifax, Nova Scotia, Canada.
Anurag BanerjeeDepartment of Pathology, Dalhousie University, Halifax, Nova Scotia, Canada.
Guido KroemerCentre de Recherche des Cordeliers, Paris, France.ORCID http://orcid.org/0000-0002-9334-4405

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A recent study by Grippin

Indexed as

Cancer VaccinesCOVID-19COVID-19 VaccinesImmune Checkpoint InhibitorsImmunotherapyNeoplasmsHumansmRNA VaccinesSARS-CoV-2Tumor MicroenvironmentCancer VaccinesCOVID-19 VaccinesImmune Checkpoint InhibitorsmRNA VaccinesImmune Checkpoint InhibitorsImmunotherapyLung CancerOncolytic virusVaccine

Identifiers

PMID42236116
PMCPMC13239367

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.